Business Wire

Motorola Solutions Delivers Unrivalled Versatility for Frontline Workers

27.10.2020 16:00:00 EET | Business Wire | Press release

Share

A global pandemic, ever-increasing volumes of data to manage and greater demand to do more with limited resources - the world has never been more complex for public safety agencies.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201027005282/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Motorola Solutions' next-generation Terrestrial Trunked Radio (TETRA) device: the MXP600 (Photo: Business Wire)

Siloed systems and devices that don’t talk with each other can add to an already existing complexity. First responders need mission-critical technology that offers an intuitive and smart experience to respond effectively in the “heat of the moment,” as well as flexible tools that enable them to connect seamlessly with a broader ecosystem of technologies.

Motorola Solutions is launching its next-generation Terrestrial Trunked Radio (TETRA) device: the smart and powerful MXP600, to meet the needs of public safety personnel today and well into the future. The lightweight yet highly rugged radio takes the proven capabilities of mission-critical voice communication to new levels and can collaborate with other solutions.

“Frontline professionals will always need their radio in high-stress situations to serve as their lifeline, but they also might require collaboration with other devices that they carry, including smartphones and body worn video cameras, without compromising the security or reliability of their radio voice communications,” said Mark Schmidl, senior vice president at Motorola Solutions.

“Instead of handling multiple devices simultaneously they can activate other devices through the one that feels most natural and intuitive to use in that situation. For example, if a police officer presses the emergency button in a life-threatening situation, the radio will in the future be able to automatically activate the body worn camera, without the officer needing to start the process separately. It's all about simplifying yet elevating key features of mission-critical communications,” explained Katja Millard, senior director devices at Motorola Solutions.

The introduction of the MXP600 will help agencies to flexibly evolve their mission-critical solutions while taking full advantage of the benefits of secure radio voice communications:

  • Be clearly heard in the noisiest environments. The MXP600 uses intelligent microphone technology to suppress background noise and has a maximum loudness that is around four times louder than a typical smartphone. When operating in windy conditions, the device automatically uses the loudspeaker as an additional microphone for optimal wind noise mitigation. When multiple radios are in close proximity, the MXP600 automatically eliminates acoustic feedback to allow for effective communication.
  • Radically accelerate device management to keep frontline workers in the field. Over-The-Air-Programming (OTAP) makes it possible for radios to be updated on-the-go and within minutes, avoiding the time, logistics and costs involved with traditional radio programming. OTAP is fast, secure and convenient to maximize the productivity of frontline workers and help to keep them in the field.
  • Flexible collaboration. Use your radio in the way that suits you best, with a smartphone app for scrolling through talkgroups, sending secure messages and discreet radio communication when you need it. The new M-RadioControl app offers a flexible way for smartphones to work alongside the MXP600. The NFC chip embedded in the MXP600 makes pairing quick and easy, while Bluetooth 5.0 means the wireless connection between radio, smartphone and other devices remains secure.

The MXP600 integrates the technologies emergency services rely upon to focus on their mission to keep the community safe.

Videos

Adaptive Mission-Critical Audio

Designed and Tested for Extreme Conditions

Frontline Safety Today And Tomorrow

Access a media kit with videos and images here.

About Motorola Solutions

Motorola Solutions is a global leader in mission-critical communications and analytics. Our technology platforms in mission-critical communications, command centre software, video security & analytics, bolstered by managed & support services, make communities safer and help businesses stay productive and secure. At Motorola Solutions, we are ushering in a new era in public safety and security. Learn more at www.motorolasolutions.com.

Follow @MotoSolutions on Twitter

Follow @MotorolaSolutions on Instagram

Follow @MotorolaSolutions on LinkedIn

Like @MotorolaSolutions on Facebook

MOTOROLA, MOTOROLA SOLUTIONS and the Stylized M Logo are trademarks or registered trademarks of Motorola Trademark Holdings, LLC and are used under license. All other trademarks are the property of their respective owners. ©2020 Motorola Solutions, Inc. All rights reserved.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Elvan Lindberg
Motorola Solutions
Mobile: +46 (0)707448893
Elvan.Lindberg@motorolasolutions.com

Susanne Stier
Motorola Solutions
Mobile: +49 (0)172 6161773
Susanne.Stier@motorolasolutions.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 20:42:00 EEST | Press release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 17:19:00 EEST | Press release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 17:15:00 EEST | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 16:00:00 EEST | Press release

inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and

Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 15:50:00 EEST | Press release

Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye